JOSEPH KLEIN III - 03 Sep 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Joseph Klein, III
Issuer symbol
IONS
Transactions as of
03 Sep 2025
Transactions value $
-$1,680,000
Form type
4
Filing time
04 Sep 2025, 20:38:01 UTC
Previous filing
02 Jul 2025
Next filing
28 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KLEIN JOSEPH III Director 2855 GAZELLE COURT, CARLSBAD By: Patrick R. O'Neil, attorney-in-fact For: Joseph Klein, III 04 Sep 2025 0001206369

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $0 +16K $0.00 16K 03 Sep 2025 by Trust
transaction IONS Common Stock Options Exercise $0 +12K +75% $0.00 28K 03 Sep 2025 by Trust
transaction IONS Common Stock Sale -$1.68M -28K -100% $60.00 0 03 Sep 2025 by Trust F1
holding IONS Common Stock 16.3K 03 Sep 2025 Direct
holding IONS Common Stock 100 03 Sep 2025 by Son F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -12K -100% $0.00 0 03 Sep 2025 Common Stock 12K $42.88 by Trust
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -16K -100% $0.00 0 03 Sep 2025 Common Stock 16K $52.22 by Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024
F2 The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.